Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.
Conference:
Presenting Author:
Authors: Grewal U, Patel R, Chandasekharan C,
Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,
Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.
Conference:
Presenting Author: Vito I
Authors: Vito I, Santillan N, Davis N, Navalkissoor S,
Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,
Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.
Conference:
Presenting Author: Cruz-Diaz W
Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,
Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,
Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).
Conference:
Presenting Author: Salcedo Cortes S
Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,
Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,
#4290 TB-161-Dotatate and Lu-177-Dotatate as a tandem therapy
Introduction: Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell-membrane specific peptide receptors, such as somatostatin receptors.
Conference:
Presenting Author:
Authors: Hambapersad T, Maharaj M,
Keywords: TB-161-Dotatate, Lu-177-Dotatate, Tandem,